|
DNMT3B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.71949999997023E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.79470000003257E-06 |
| Normal-vs-Stage2 |
6.779500E-02 |
| Normal-vs-Stage3 |
2.19989999999948E-05 |
| Normal-vs-Stage4 |
6.06660000013193E-07 |
| Stage1-vs-Stage2 |
2.547200E-01 |
| Stage1-vs-Stage3 |
4.427000E-01 |
| Stage1-vs-Stage4 |
1.442220E-01 |
| Stage2-vs-Stage3 |
1.142210E-01 |
| Stage2-vs-Stage4 |
4.973900E-02 |
| Stage3-vs-Stage4 |
4.257200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.70790999999282E-05 |
| Normal-vs-AfricanAmerican |
5.353200E-04 |
| Normal-vs-Asian |
1.80069999999866E-05 |
| Caucasian-vs-AfricanAmerican |
4.939000E-01 |
| Caucasian-vs-Asian |
4.625000E-01 |
| AfricanAmerican-vs-Asian |
8.067800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.213600E-04 |
| Normal-vs-Female |
1.53280000003697E-06 |
| Male-vs-Female |
3.338000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.04839999999873E-05 |
| Normal-vs-Age(41-60Yrs) |
1.34850000055309E-08 |
| Normal-vs-Age(61-80Yrs) |
3.416700E-03 |
| Normal-vs-Age(81-100Yrs) |
8.738100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.405400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.883600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.493400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.534800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.154400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.549000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.30340000015217E-07 |
| Classical-VS-Follicular |
4.414700E-04 |
| Classical-VS-Other |
4.794200E-01 |
| Classical-VS-Normal |
1.87249999950012E-08 |
| Tall-VS-Follicular |
2.65239996632971E-09 |
| Tall-VS-Other |
1.326990E-01 |
| Tall-VS-Normal |
4.16000567327046E-13 |
| Follicular-VS-Other |
5.091800E-01 |
| Follicular-VS-Normal |
3.746800E-01 |
| Other-VS-Normal |
1.515390E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.168200E-04 |
| Normal-vs-N1 |
2.08849999999705E-05 |
| N0-vs-N1 |
1.045980E-01 |
|
|
